Sumatriptan — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Migraine

• Amitriptyline
• Propranolol
• Rizatriptan
• Topiramate

Other medications in Neurological

• Teriflunomide
• Tiagabine
• Trihexyphenidyl
• Ubrogepant
• Valproate IV
• Vigabatrin
• Zonisamide
• Alemtuzumab

About Sumatriptan

Sumatriptan is a widely prescribed medication known for its effectiveness in treating debilitating migraine and cluster headaches. For those struggling with severe head pain, quick and affordable access to relief is crucial. TheDrugClub is dedicated to making essential medications like sumatriptan accessible, offering significant savings and convenience to our members.

Sumatriptan is primarily used to treat acute migraine attacks, with or without aura, and acute cluster headaches. It is not intended for preventing these headaches but rather for relieving the pain and associated symptoms once they have started. This medication can significantly reduce headache pain, nausea, sensitivity to light and sound, and other debilitating symptoms that often accompany migraines, allowing individuals to resume their daily activities sooner and with greater comfort.

Sumatriptan belongs to a class of drugs called selective serotonin receptor agonists, commonly known as triptans. It works by targeting specific serotonin receptors (5-HT1B/1D) in the brain. During a migraine attack, blood vessels in the brain can become dilated and inflamed. Sumatriptan helps to constrict these blood vessels back to their normal size, reducing the swelling and inflammation that contribute to migraine pain. It also helps to block pain signals from being sent to the brain, providing comprehensive relief. For optimal effectiveness, it's generally recommended to take sumatriptan at the first sign of a migraine or cluster headache.

The cost of sumatriptan can vary significantly depending on whether you're prescribed the generic version or the brand-name Imitrex, the specific dosage, and the form (tablets, nasal spray, or injectable). Without insurance, a typical prescription for generic sumatriptan tablets might range from $20 to $60 for a pack of 9 tablets. Brand-name versions or other forms can be considerably more expensive, sometimes costing hundreds of dollars for a single prescription. These fluctuating costs can be a significant financial burden for many individuals, especially those who experience frequent migraines and rely on this essential medication

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Sumatriptan is approved for (FDA label)

Sumatriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: • Use only if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with sumatriptan, reconsider the diagnosis of migraine before sumatriptan is administered to treat any subsequent attacks. • Sumatriptan is not indicated for the prevention of migraine attacks. • Safety and effectiveness of sumatriptan tablets have not been established for cluster headache. Sumatriptan is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for acute treatment of migraine with or without aura in adults.

Source: Read the full FDA label on DailyMed. Label effective date: September 3, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Sumatriptan (FDA label)

25 mg Tablets: yellow colored, film coated, triangular biconvex debossed with “S” on one side and “102” on the other side. 50 mg Tablets: pink colored, film coated, triangular biconvex debossed with “S” on one side and “103” on the other side. 100 mg Tablets: white to off white, film coated, triangular biconvex debossed with “S” on one side and “104” on the other side. Tablets: 25 mg, 50 mg, and 100 mg

Source: FDA prescribing information (DailyMed). Set ID: ff08b9ee-03bf-4f5b-930e-233a3b8866af. SPL document ID: ae033996-da87-4e37-953f-784bcfb68f2c. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Sumatriptan (FDA label)

The following adverse reactions are discussed in more detail in other sections of the prescribing information: • Myocardial ischemia, myocardial infarction, and Prinzmetal’s angina [see Warnings and Precautions (5.1)] • Arrhythmias [see Warnings and Precautions (5.2)] • Chest, throat, neck, and/or jaw pain/tightness/pressure [see Warnings and Precautions (5.3)] • Cerebrovascular events [see Warnings and Precautions (5.4)] • Other vasospasm reactions [see Warnings and Precautions (5.5)] • Medication overuse headache [see Warnings and Precautions (5.6)] • Serotonin syndrome [see Warnings and Precautions (5.7)] • Increase in blood pressure [see Warnings and Precautions (5.8)] • Hypersensitivity reactions [see Contraindications (4), Warnings and Precautions (5.9)] • Seizures [see Warnings and Precautions (5.10)] Most common adverse reactions (≥2% and >placebo) were paresthesia, warm/cold sensation, chest pain/tightness/pressure and/or heaviness, neck/throat/jaw pain/tightness/pressure, other sensations of pain/pressure/tightness/heaviness, vertigo, and malaise/fatigue. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Bionpharma Inc. at 1-888-235-BION or 1-888-235-2466 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: ff08b9ee-03bf-4f5b-930e-233a3b8866af. SPL document ID: ae033996-da87-4e37-953f-784bcfb68f2c. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Sumatriptan (FDA label)

Sumatriptan tablets are contraindicated in patients with: • Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal’s angina [see Warnings and Precautions (5.1)] • Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2)] • History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [s ee Warnings and Precautions (5.4)] • Peripheral vascular disease [see Warnings and Precautions (5.5)] • Ischemic bowel disease [see Warnings and Precautions (5.5)] • Uncontrolled hypertension [see Warnings and Precautions (5.8)] • Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine 1 (5-HT 1 ) agonist [see Drug Interactions (7.1, 7.3)]

Source: FDA prescribing information (DailyMed). Set ID: ff08b9ee-03bf-4f5b-930e-233a3b8866af. SPL document ID: ae033996-da87-4e37-953f-784bcfb68f2c. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Sumatriptan (FDA label)

• Myocardial ischemia/infarction and Prinzmetal’s angina: Perform cardiac evaluation in patients with multiple cardiovascular risk factors. (5.1) • Arrhythmias: Discontinue sumatriptan if occurs. (5.2) • Chest/throat/neck/jaw pain, tightness, pressure, or heaviness: Generally not associated with myocardial ischemia; evaluate for coronary artery disease in patients at high risk. (5.3) • Cerebral hemorrhage, subarachnoid hemorrhage, and stroke: Discontinue sumatriptan if occurs. (5.4) • Gastrointestinal ischemic reactions and peripheral vasospastic reactions: Discontinue sumatriptan if occurs. (5.5) • Medication overuse headache: Detoxification may be necessary. (5.6) • Serotonin syndrome: Discontinue sumatriptan if occurs. (5.7) • Seizures: Use with caution in patients with epilepsy or a lowered seizure threshold. (5.10) 5.1 Myocardial Ischemia, Myocardial Infarction, and Prinzmetal’s Angina The use of sumatriptan tablets is contraindicated in patients with ischemic or vasospastic CAD. There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of sumatriptan tablets.

Source: FDA prescribing information (DailyMed). Set ID: ff08b9ee-03bf-4f5b-930e-233a3b8866af. SPL document ID: ae033996-da87-4e37-953f-784bcfb68f2c. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Sumatriptan (FDA label)

7.1 Ergot-Containing Drugs Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan tablets within 24 hours of each other is contraindicated. 7.2 Monoamine Oxidase-A Inhibitors MAO‑A inhibitors increase systemic exposure by 7 fold. Therefore, the use of sumatriptan tablets in patients receiving MAO‑A inhibitors is contraindicated [see Clinical Pharmacology (12.3)] . 7.3 Other 5-HT 1 Agonists Because their vasospastic effects may be additive, coadministration of sumatriptan tablets and other 5‑HT 1 agonists (e.g., triptans) within 24 hours of each other is contraindicated. 7.4 Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.7)] .

Source: FDA prescribing information (DailyMed). Set ID: ff08b9ee-03bf-4f5b-930e-233a3b8866af. SPL document ID: ae033996-da87-4e37-953f-784bcfb68f2c. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.